Comparative Pharmacology
Head-to-head clinical analysis: EXELDERM versus LOTRISONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXELDERM versus LOTRISONE.
EXELDERM vs LOTRISONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Topical antimycotic that inhibits fungal squalene epoxidase, leading to accumulation of squalene and disruption of fungal cell wall synthesis.
Lotrisone combines betamethasone dipropionate, a corticosteroid that binds to glucocorticoid receptors, modulating gene expression to reduce inflammation, and clotrimazole, an imidazole antifungal that inhibits CYP51 (lanosterol 14alpha-demethylase), disrupting ergosterol synthesis and fungal cell membrane integrity.
Apply a thin layer to affected skin twice daily (morning and evening).
Apply a thin film to affected skin areas twice daily, morning and evening, for 2 weeks.
None Documented
None Documented
Not applicable due to negligible systemic absorption; after topical application, half-life in skin is several hours.
Clotrimazole: 3.5-6 hours (topical, minimal systemic absorption); betamethasone dipropionate: approximately 4-6 hours for betamethasone after hydrolysis.
Systemic absorption is minimal; any absorbed sulconazole is primarily metabolized in the liver and excreted in feces via bile; renal excretion of unchanged drug is negligible.
Clotrimazole: <0.5% of dose excreted unchanged in urine; betamethasone dipropionate: primarily renal (<5% unchanged) and biliary/fecal (35-50% as metabolites).
Category C
Category C
Topical Antifungal
Topical Antifungal/Corticosteroid Combination